A biosimilar that achieves interchangeable status can be substituted for the reference product by a pharmacist in most states without contacting the prescriber the same automatic substitution that applies to small-molecule AB-rated generics
Ive observed that there are 5 obstacles patients experience with these medications as treatments for obesity and diabetes: Cost of the meds Side effects and tolerability Fear of needles Concerns about safety The moral failing of needing a medication Oral GLP1 drugs like orforglipron (Foundayo) and Wegovy work almost as well as the injectable version of these drugs The FDA just approved oral Foundayo for the treatment of obesity based on the results of the ATTAIN-1 trial, recently published in NEJM
In addition, leptin administration reverses the effects of sustained weight reduction on energy expenditure 2, 4
17 Many employers have excluded weight loss drugs from their health insurance plans due to the high costs associated with treating large numbers of people.6,7 Patients typically pay $100 to $450 a month for a compounded version, compared with list prices of roughly $1,000 to $1,400 monthly for name brand products
Shipping was just a bit slow
However, no causal connection between these events and desmopressin acetate has been established